Elsubrutinib
M20-186
Phase 2 small_molecule completed
Quick answer
Elsubrutinib for Systemic Lupus Erythematosus (SLE) is a Phase 2 program (small_molecule) at AbbVie with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie
- Indication
- Systemic Lupus Erythematosus (SLE)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed